IL2 and neoplasm: Moreover, when combined with the immune checkpoint blocker nivolumab, IL-2 significantly inhibits tumor growth in cancers such as melanoma, RCC, NSCLC, uroepithelial carcinoma, and triple-negative breast cancer (TNBC) [69].